| Basics |
Biohaven Pharmaceutical Holding Company Ltd.
Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders.
|
| IPO Date: |
May 11, 2017 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$2.1B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$1.24 | 2.60%
|
| Avg Daily Range (30 D): |
$1.03 | 4.68%
|
| Avg Daily Range (90 D): |
$1.01 | 3.37%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.71M |
| Avg Daily Volume (30 D): |
1.63M |
| Avg Daily Volume (90 D): |
1.12M |
| Trade Size |
| Avg Trade Size (Sh.): |
79 |
| Avg Trade Size (Sh.) (30 D): |
78 |
| Avg Trade Size (Sh.) (90 D): |
68 |
| Institutional Trades |
| Total Inst.Trades: |
5,115 |
| Avg Inst. Trade: |
$3.12M |
| Avg Inst. Trade (30 D): |
$2.18M |
| Avg Inst. Trade (90 D): |
$2.55M |
| Avg Inst. Trade Volume: |
.06M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$5.02M |
| Avg Closing Trade (30 D): |
$4.02M |
| Avg Closing Trade (90 D): |
$5.21M |
| Avg Closing Volume: |
102.12K |
|
|
|
|
| Financials |
| |
TTM |
Q2 2024 |
Q1 2024 |
|
Basic EPS
|
$-1.7
|
$-3.64
|
$-2.2
|
|
Diluted EPS
|
$-1.7
|
$-3.64
|
$-2.2
|
|
Revenue
|
$ M
|
$ M
|
$ M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -160.3M
|
$ -319.77M
|
$ -179.5M
|
|
Operating Income / Loss
|
$ -178.17M
|
$ -333.77M
|
$ -183.24M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ -154.3M
|
$ 55.39M
|
$ -65.19M
|
|
PE Ratio
|
|
|
|
|
